Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Annovis Bio (NYSE:ANVS) through any online brokerage.
Other companies in Annovis Bio’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Annovis Bio has a consensus price target of $27.88.
The stock price for Annovis Bio (NYSE: ANVS) is $1.1568 last updated October 12, 2026 at 12:47 PM EDT.
There are no upcoming dividends for Annovis Bio.
Annovis Bio does not have any upcoming earnings scheduled.
There is no upcoming split for Annovis Bio.
Annovis Bio is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.